Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1996 3
1997 1
1998 1
1999 1
2004 2
2010 3
2011 3
2012 6
2013 6
2014 4
2015 7
2016 7
2017 2
2018 4
2019 5
2020 5
2021 11
2022 10
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: eberlein c. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: eberlein c. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K. Dunn S, et al. Among authors: eberlein c. Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14. Oncogene. 2022. PMID: 36241868 Free PMC article.
Aripiprazole treatment for temper outbursts in Prader-Willi syndrome.
Deest M, Wieting J, Jakob MM, Deest-Gaubatz S, Groh A, Seifert J, Toto S, Bleich S, Frieling H, Eberlein CK. Deest M, et al. Among authors: eberlein ck. Orphanet J Rare Dis. 2022 Aug 26;17(1):324. doi: 10.1186/s13023-022-02470-y. Orphanet J Rare Dis. 2022. PMID: 36028863 Free PMC article.
Genetic Cell-Surface Modification for Optimized Foam Fractionation.
Blesken CC, Bator I, Eberlein C, Heipieper HJ, Tiso T, Blank LM. Blesken CC, et al. Among authors: eberlein c. Front Bioeng Biotechnol. 2020 Oct 29;8:572892. doi: 10.3389/fbioe.2020.572892. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33195133 Free PMC article.
Behavioural change in Prader-Willi syndrome during COVID-19 pandemic.
Wieting J, Eberlein C, Bleich S, Frieling H, Deest M. Wieting J, et al. Among authors: eberlein c. J Intellect Disabil Res. 2021 Jul;65(7):609-616. doi: 10.1111/jir.12831. Epub 2021 Mar 22. J Intellect Disabil Res. 2021. PMID: 33754414 Free PMC article.
nPhase: an accurate and contiguous phasing method for polyploids.
Abou Saada O, Tsouris A, Eberlein C, Friedrich A, Schacherer J. Abou Saada O, et al. Among authors: eberlein c. Genome Biol. 2021 Apr 29;22(1):126. doi: 10.1186/s13059-021-02342-x. Genome Biol. 2021. PMID: 33926549 Free PMC article.
85 results